Cover Image
市場調查報告書

Pharmaxis Limited - 產品平台分析

Pharmaxis Limited - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 251704
出版日期 內容資訊 英文 35 Pages
訂單完成後即時交付
價格
Back to Top
Pharmaxis Limited - 產品平台分析 Pharmaxis Limited - Product Pipeline Review - 2015
出版日期: 2015年10月30日 內容資訊: 英文 35 Pages
簡介

Pharmaxis Ltd. ha正在開發慢性呼吸疾病及免疫障礙的診斷和治療用產品。

本報告提供Pharmaxis Limited的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Pharmaxis Limited的基本資料

Pharmaxis Limited概要

  • 主要資訊
  • 企業資料

Pharmaxis Limited:R&D概要

  • 主要的治療範圍

Pharmaxis Limited:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Pharmaxis Limited:開發中產品概況

  • 最後階段的開發中產品
    • 申請但不受理/被撤消的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Pharmaxis Limited:藥物簡介

  • mannitol
  • ASM-8
  • PXS-25
  • PXS-64
  • PXS-2200
  • PXS-4159
  • PXS-4206
  • PXS-4681A
  • PXS-4728A
  • PXSTPI-1100
  • Small Molecules to Inhibit LOXL2 for Oncology and Fibrosis
  • PXS-4820
  • PXS-5033-A

Pharmaxis Limited:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Pharmaxis Limited:最近的開發平台趨勢

Pharmaxis Limited:暫停中的計劃

Pharmaxis Limited:總公司和子公司的所地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07696CDB

Summary

Global Markets Direct's, 'Pharmaxis Limited - Product Pipeline Review - 2015', provides an overview of the Pharmaxis Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pharmaxis Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Pharmaxis Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Pharmaxis Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Pharmaxis Limited's pipeline products

Reasons to buy

  • Evaluate Pharmaxis Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Pharmaxis Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Pharmaxis Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Pharmaxis Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pharmaxis Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Pharmaxis Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Pharmaxis Limited Snapshot
    • Pharmaxis Limited Overview
    • Key Information
    • Key Facts
  • Pharmaxis Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Pharmaxis Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Pharmaxis Limited - Pipeline Products Glance
    • Pharmaxis Limited - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Pharmaxis Limited - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Pharmaxis Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Pharmaxis Limited - Drug Profiles
    • mannitol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASM-8
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PXS-2200
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PXS-4681A
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit LOXL2 for Oncology and Idiopathic Pulmonary Fibrosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PXS-4820
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PXS-5033A
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Pharmaxis Limited - Pipeline Analysis
    • Pharmaxis Limited - Pipeline Products by Target
    • Pharmaxis Limited - Pipeline Products by Route of Administration
    • Pharmaxis Limited - Pipeline Products by Molecule Type
    • Pharmaxis Limited - Pipeline Products by Mechanism of Action
  • Pharmaxis Limited - Recent Pipeline Updates
  • Pharmaxis Limited - Dormant Projects
  • Pharmaxis Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Pharmaxis Limited, Key Information
  • Pharmaxis Limited, Key Facts
  • Pharmaxis Limited - Pipeline by Indication, 2015
  • Pharmaxis Limited - Pipeline by Stage of Development, 2015
  • Pharmaxis Limited - Monotherapy Products in Pipeline, 2015
  • Pharmaxis Limited - Phase III, 2015
  • Pharmaxis Limited - Phase II, 2015
  • Pharmaxis Limited - Preclinical, 2015
  • Pharmaxis Limited - Discovery, 2015
  • Pharmaxis Limited - Pipeline by Target, 2015
  • Pharmaxis Limited - Pipeline by Route of Administration, 2015
  • Pharmaxis Limited - Pipeline by Molecule Type, 2015
  • Pharmaxis Limited - Pipeline Products by Mechanism of Action, 2015
  • Pharmaxis Limited - Recent Pipeline Updates, 2015
  • Pharmaxis Limited - Dormant Developmental Projects,2015
  • Pharmaxis Limited, Subsidiaries

List of Figures

  • Pharmaxis Limited - Pipeline by Top 10 Indication, 2015
  • Pharmaxis Limited - Pipeline by Stage of Development, 2015
  • Pharmaxis Limited - Monotherapy Products in Pipeline, 2015
  • Pharmaxis Limited - Pipeline by Top 10 Target, 2015
  • Pharmaxis Limited - Pipeline by Top 10 Route of Administration, 2015
  • Pharmaxis Limited - Pipeline by Top 10 Molecule Type, 2015
  • Pharmaxis Limited - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top